register

News & Trends - Biotechnology

BioCurate moves to next phase of growth with appointment of acting CEO

Health Industry Hub | February 15, 2021 |

Biotech News: BioCurate, an independently operated joint venture between the University of Melbourne and Monash University, and with support of the Victorian State Government, appoints Dr Damien Bates as Acting CEO, with Founding CEO Dr C. Glenn Begley transitioning to a specialist scientific, commercial and strategic advisory role for the organisation.

An internationally experienced biotech executive, Dr Damien Bates joined BioCurate as Chief Scientific Officer and Head of Translational Medicine nearly two years ago. He has played a critical role in driving the progression of projects along their respective development pathways through close collaborations with the Universities’ researchers and innovation staff, implementation of industry best practice across all aspects of project management, portfolio evaluation, industry engagement and resource allocation, and strong staff support and management.

BioCurate Chairperson the Hon John Brumby AO said the leadership transition marked a critical next step for the company’s development.

We have a well-developed project portfolio, a highly-skilled and committed team, and an excellent relationship with our Shareholder Universities. As Founding CEO, Glenn has made an outstanding contribution to BioCurate and we thank him for his untiring efforts to deliver our vision.

“We welcome Damien, who already knows the business well and has been the driving force behind the progress of our projects. We believe he will bring new energy, breadth of knowledge and focused leadership to all areas of the business,” Mr Brumby said.

As Founding CEO of BioCurate, Dr Begley’s expertise and his deep international experience, together with his passionate commitment to helping drive quality research and translation within the university and medical research sector, has been instrumental to BioCurate’s foundational success. He has led the growth and success of BioCurate through a number of the critical stages including building BioCurate’s investment portfolio of highly prospective projects through the review of > 100 early-stage research projects.

“I am most proud of the staff and team culture that BioCurate has built and remain fully committed to the vision. I am delighted with Damien’s appointment – he, COO Linda Peterson and the BioCurate team, have my unwavering support. I look forward to supporting them as the company moves through its next exciting phase,” Dr Begley said.

Dr Bates said “It is a great privilege to take over the reins from Glenn. I am looking forward to continuing to work closely with the Board, Shareholders and staff to support research that has commercial potential, and driving projects through to fruition – thereby getting one step closer to realising our mission of translating medical research outputs into high quality preclinical candidates for the bio-pharmaceutical industry and eventually new safe & effective therapies for the community.”

You may also like CSL manufacturing of AstraZeneca COVID-19 vaccine reaches final stages


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.